Analyst Price Targets — BHVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2026 10:10 am | — | Needham | $11.00 | $15.83 | StreetInsider | BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform |
| May 13, 2026 12:01 pm | Terence Flynn | Morgan Stanley | $18.00 | $8.93 | TheFly | Biohaven price target lowered to $18 from $21 at Morgan Stanley |
| March 4, 2026 11:41 am | Douglas Tsao | H.C. Wainwright | $10.00 | $10.39 | StreetInsider | Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright |
| March 3, 2026 7:43 pm | Marc Goodman | Leerink Partners | $15.00 | $10.67 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates |
| February 5, 2026 9:18 pm | — | Goldman Sachs | $23.00 | $10.76 | TheFly | Biohaven initiated with a Buy at Goldman Sachs |
| January 21, 2026 10:09 am | — | RBC Capital | $22.00 | $12.68 | TheFly | Biohaven upgraded to Outperform from Sector Perform at RBC Capital |
| December 3, 2025 11:08 am | — | H.C. Wainwright | $11.00 | $8.83 | TheFly | Biohaven downgraded to Neutral from Buy at H.C. Wainwright |
| November 26, 2025 9:57 am | — | UBS | $11.00 | $9.24 | TheFly | Biohaven downgraded to Neutral from Buy at UBS |
| November 18, 2025 2:26 pm | — | Morgan Stanley | $26.00 | $9.45 | TheFly | Biohaven price target lowered to $26 from $54 at Morgan Stanley |
| November 5, 2025 11:09 am | Brian Skorney | Robert W. Baird | $42.00 | $13.95 | StreetInsider | Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird |
Latest News for BHVN
Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform.
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile In the ongoing focal epilepsy open-label extension (OLE) study, 54% of…
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial.
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHVN.
U.S. House Trading
No House trades found for BHVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.